We are a development stage orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. Our proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable currently while others are in various stages of development. The Company's first approved product using its collagen matrix technology is the CMI, a meniscus implant cleared for sale in the European Union ("EU") and marketed through the Company's European subsidiary, ReGen Biologics AG. We have made a 510(k) premarket notification submission to the FDA for market clearance in the U.S. of the Collagen Scaffold device, which includes an application for the reinforcement and repair of meniscus defects.